<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311435534</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311435534</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Kulwinder</given-names></name>
<xref ref-type="fn" rid="fn1-1470320311435534">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sharma</surname><given-names>Kuldeepak</given-names></name>
<xref ref-type="fn" rid="fn1-1470320311435534">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Manjeet</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Sharma</surname><given-names>PL</given-names></name>
</contrib>
<aff id="aff1-1470320311435534">ISF College of Pharmacy, Moga, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1470320311435534">PL Sharma, Department of Pharmacology, ISF College of Pharmacy, Moga 142 001, India. Email: <email>ksjajjal77@rediffmail.com</email></corresp>
<fn fn-type="other" id="fn1-1470320311435534">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<fpage>334</fpage>
<lpage>340</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1470320311435534">
<title>Hypothesis:</title>
<p>This study was designed to investigate the cardio-renal protective effect of AVE-0991, a non-peptide Mas-receptor agonist, and A-779, a Mas-receptor antagonist, in diabetic rats.</p>
</sec>
<sec id="section2-1470320311435534">
<title>Materials and methods:</title>
<p>Wistar rats treated with streptozotocin (50 mg/kg, i.p., once), developed diabetes mellitus after 1 week. After 8 weeks, myocardial functions were assessed by measuring left ventricular developed pressure (LVDP), rate of left ventricular pressure development (d<italic>p</italic>/d<italic>t</italic><sub>max</sub>), rate of left ventricular pressure decay (d<italic>p</italic>/d<italic>t</italic><sub>min</sub>) and left ventricular end diastolic pressure (LVEDP) on an isolated Langendorff’s heart preparation. Further, mean arterial blood pressure (MABP) was measured by using the tail-cuff method. Assessment of renal functions and lipid profile was carried out using a spectrophotometer.</p>
</sec>
<sec id="section3-1470320311435534">
<title>Results:</title>
<p>The administration of streptozotocin to rats produced persistent hyperglycaemia, dyslipidaemia and hypertension which consequently produced cardiac and renal dysfunction in 8 weeks. AVE0991 treatment produced cardio-renal protective effects, as evidenced by a significant increase in LVDP, d<italic>p</italic>/d<italic>t</italic><sub>max</sub>, d<italic>p</italic>/d<italic>t</italic><sub>min</sub> and a significant decrease in LVEDP, BUN, and protein urea. Further, AVE-0991 treatment for the first time has been shown to reduce dyslipidaemia and produced antihyperglycaemic activity in streptozotocin-treated rats. However, MABP and creatinine clearance remained unaffected with AVE-0991 treatment.</p>
</sec>
<sec id="section4-1470320311435534">
<title>Conclusions:</title>
<p>AVE-0991 produced cardio-renal protection possibly by improving glucose and lipid metabolism in diabetic rats, independent of its blood pressure lowering action.</p>
</sec>
</abstract>
<kwd-group>
<kwd>A-779</kwd>
<kwd>AVE-0991</kwd>
<kwd>diabetes mellitus</kwd>
<kwd>lipids</kwd>
<kwd>Mas receptor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1470320311435534" sec-type="intro">
<title>Introduction</title>
<p>Diabetes mellitus (DM) is an independent risk for cardiovascular (CV) disease in patients with dyslipidaemia and renal dysfunction.<sup><xref ref-type="bibr" rid="bibr1-1470320311435534">1</xref></sup> Over-activation of the renin–angiotensin–aldosterone system (RAAS) is a possible molecular mechanism for development and progression of CV and renal dysfunction in diabetes.<sup><xref ref-type="bibr" rid="bibr2-1470320311435534">2</xref>,<xref ref-type="bibr" rid="bibr3-1470320311435534">3</xref></sup></p>
<p>Angiotensin converting enzyme-2 (ACE-2), is a negative regulator of RAAS, which hydrolyses angiotensin I and angiotensin II to angiotensin (1–7),<sup><xref ref-type="bibr" rid="bibr4-1470320311435534">4</xref></sup> which produces vasodilation, antiproliferative and natriuretic activity in normal rats and antidiuretic acitivity in water-loaded rats through activation of the Mas receptor.<sup><xref ref-type="bibr" rid="bibr5-1470320311435534">5</xref>,<xref ref-type="bibr" rid="bibr6-1470320311435534">6</xref></sup> Chronic inhibition of ACE-2 and ACE-2 knockout in mice has been reported to worsen glomerular injury and nephropathy.<sup><xref ref-type="bibr" rid="bibr7-1470320311435534">7</xref></sup> Recently, our research group showed that chronic treatment with angiotensin (1–7) attenuated dyslipidaemia and BUN in diabetic rats with nephropathy.<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref></sup></p>
<p>Further, angiotensin (1–7) ameliorates cardiac remodelling by decreasing hypertrophy and fibrosis,<sup><xref ref-type="bibr" rid="bibr9-1470320311435534">9</xref>,<xref ref-type="bibr" rid="bibr10-1470320311435534">10</xref></sup> while genetic depletion of Mas resulted in dyslipidaemia, insulin resistance and marked fibrotic and hypertrophic changes in rat myocardium.<sup><xref ref-type="bibr" rid="bibr11-1470320311435534">11</xref>,<xref ref-type="bibr" rid="bibr12-1470320311435534">12</xref></sup> It has been documented that chronic administration of angiotensin (1–7) prevented diabetes-induced cardiovascular dysfunction.<sup><xref ref-type="bibr" rid="bibr13-1470320311435534">13</xref>,<xref ref-type="bibr" rid="bibr14-1470320311435534">14</xref></sup></p>
<p>The major limitation of exogenous administration of angiotensin (1–7) is that it is a peptide, with a very short biological half-life, low oral bioavailability and is very low stability.<sup><xref ref-type="bibr" rid="bibr11-1470320311435534">11</xref></sup> Because of these limitations, angiotensin (1–7) is generally administered subcutaneously by osmotic mini pumps, which are quite expensive and are not readily available.</p>
<p>AVE-0991, a non-peptide Mas-receptor agonist synthesised by sanofi–aventis (Frankfurt, Germany)<sup><xref ref-type="bibr" rid="bibr12-1470320311435534">12</xref></sup> has been reported to mimic the action of angiotensin (1–7) in many tissues by its vasodilating and natriuretic properties.<sup><xref ref-type="bibr" rid="bibr6-1470320311435534">6</xref>,<xref ref-type="bibr" rid="bibr12-1470320311435534">12</xref></sup> Moreover, AVE-0991 has a longer biological half-life and is more stable than angiotensin (1–7). Therefore, the present study was designed to investigate the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, and A-779, a Mas-receptor antagonist, in diabetic rats.</p>
</sec>
<sec id="section6-1470320311435534" sec-type="materials|methods">
<title>Materials and methods</title>
<p>The experimental protocol used in the present study was approved by the Institutional Animal Ethical Committee. Age-matched young Wistar rats, weighing about 200–250 g, were employed in the present study. Rats were fed on standard chow diet and water <italic>ad libitum</italic>. They were acclimatised in animal house and were exposed to normal cycle of light and darkness.</p>
<sec id="section7-1470320311435534">
<title>Induction of experimental diabetes mellitus</title>
<p>Diabetes was induced by a single injection of streptozotocin (STZ, 50 mg/kg, i.p.) dissolved in freshly prepared ice-cold citrate buffer (pH 4.5). After 1 week of STZ administration animals with a random serum glucose of more than 240 mg/dl were considered as diabetic. The cardiovascular and renal dysfunction develops after 8 weeks of STZ administration as reported earlier.<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref>,<xref ref-type="bibr" rid="bibr14-1470320311435534">14</xref></sup></p>
</sec>
<sec id="section8-1470320311435534">
<title>Drugs and chemicals</title>
<p>STZ was obtained from Sigma Aldrich (St Louis, Missouri, USA). A-779 was obtained from BACHEM (Bubendorf, Switzerland). AVE-0991 was obtained from sanofi–aventis, <italic>ex gratia</italic>. All other chemicals used in present study were of analytical grade.</p>
</sec>
<sec id="section9-1470320311435534">
<title>Experimental protocol</title>
<p>Seven groups were used in the present study and each group comprised seven to nine rats of either sex. AVE-0991 and A-779 were dissolved in normal saline (0.9% w/v).</p>
<list id="list1-1470320311435534" list-type="bullet">
<list-item><p>Group 1 (normal control): Rats were maintained on standard food and water regime and no treatment was given.</p></list-item>
<list-item><p>Group II (AVE-0991 <italic>per se</italic>): Rats were administered AVE-0991 (576 μg/kg/day i.p.)<sup><xref ref-type="bibr" rid="bibr13-1470320311435534">13</xref></sup> from week 5 to week 8.</p></list-item>
<list-item><p>Group III (A-779 <italic>per se</italic>): Rats were treated with A-779 (744 μg/kg/day i.p., 4 weeks)<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref></sup> from week 5 to week 8.</p></list-item>
<list-item><p>Group IV (diabetic control): Rats were administered STZ (50 mg/kg, i.p., once) dissolved in citrate buffer (pH 4.5).</p></list-item>
<list-item><p>Group V (AVE-0991 treated diabetic group): Rats were treated with AVE-0991 (576 μg/kg/day i.p., 4 weeks), 4 weeks following STZ administration.</p></list-item>
<list-item><p>Group VI (A-779 treated diabetic group): Rats were treated with A-779 (744 μg/kg/day i.p., 4 weeks) 4 weeks following STZ administration.</p></list-item>
<list-item><p>Group VII (A-779 + AVE-0991 treated diabetic group): Rats were treated with A-779 (744 μg/kg/day i.p., 4 weeks) 30 min before treatment with AVE-0991 (576 μg/kg/day i.p., 4 weeks), 4 weeks following STZ administration.</p></list-item>
</list>
</sec>
<sec id="section10-1470320311435534">
<title>Assessment of serum glucose and lipid profile</title>
<p>At the end of the experimental protocol, the venous blood samples were collected from the retro-orbital sinus under light ether anaesthesia and serum was separated. The serum samples were frozen at −20°C until required for the analysis of biochemical parameters. The serum glucose concentration was estimated by the glucose oxidase–peroxidase (GOD-POD) method,<sup><xref ref-type="bibr" rid="bibr16-1470320311435534">16</xref></sup> serum total cholesterol was estimated by the cholesterol oxidase–peroxidase (CHOD-POD) method,<sup><xref ref-type="bibr" rid="bibr17-1470320311435534">17</xref></sup> serum triglyceride was estimated by glycerophosphate oxidase–peroxidase (GPO-PAP) method,<sup><xref ref-type="bibr" rid="bibr16-1470320311435534">16</xref></sup> and serum high density lipoprotein (HDL) was estimated by the cholesterol oxidase–peroxidase (CHOD-POD) method<sup><xref ref-type="bibr" rid="bibr16-1470320311435534">16</xref></sup> using commercially available kits (Coral Clinical System, Goa, India).</p>
<p>Total tissue lipids were extracted and washed with Folch wash reagent.<sup><xref ref-type="bibr" rid="bibr18-1470320311435534">18</xref>,<xref ref-type="bibr" rid="bibr19-1470320311435534">19</xref></sup> For determination of LV triglycerides, LV cholesterol, renal triglycerides and renal cholesterol, dried total lipid extract was dissolved in peroxide-free dioxane/isopropanol<sup><xref ref-type="bibr" rid="bibr20-1470320311435534">20</xref></sup> and aliquots were taken for estimation using the commercially available kit (Coral Clinical System,) according to previously described methods, i.e. the GPO-PAP method and CHOD-POD method, respectively.</p>
</sec>
<sec id="section11-1470320311435534">
<title>Assessment of renal function</title>
<p>Serum creatinine and urinary creatinine concentrations were estimated with the alkaline picrate method.<sup><xref ref-type="bibr" rid="bibr21-1470320311435534">21</xref></sup> Creatinine clearance was estimated with a formula using serum creatinine and urinary creatinine,<sup><xref ref-type="bibr" rid="bibr22-1470320311435534">22</xref></sup> BUN was estimated by the Berthelot method<sup><xref ref-type="bibr" rid="bibr23-1470320311435534">23</xref></sup> and urinary protein was estimated with the pyragallol red method.<sup><xref ref-type="bibr" rid="bibr24-1470320311435534">24</xref></sup> Kits for these measurements were purchased from Coral Clinical System.</p>
</sec>
<sec id="section12-1470320311435534">
<title>Haemodynamic assessments</title>
<p>Mean arterial blood pressure (MABP) was recorded before induction of diabetes (basal) and at the end of the study, using non-invasive blood pressure measurement by the tail-cuff method (NIBP-Biopac-MP 100; Goleta, California, USA). The animals were restrained and conditioned for 5 days before commencing blood pressure measurements. The rat tail was heated with a 200 W heat lamp for 3–5 min. At least three separate indirect pressures were averaged for each animal.<sup><xref ref-type="bibr" rid="bibr25-1470320311435534">25</xref></sup></p>
<p>After a study period of 8 weeks, the rats were sacrificed by spinal dislocation, the thorax was opened and the heart was excised after intraperitonial heparinisation (500 U/kg body weight) and placed into chilled, heparinised perfusate to arrest the beating of the heart. The heart was immediately mounted on a digital Langendorff’s apparatus (RADNOTI, Monrovia, California, USA) and perfused with Krebs–Henseleit solution (NaCl 118 mM, KCl 4.7 mM, CaCl<sub>2</sub> 2.5 mM, MgSO<sub>4</sub><bold>·</bold>7H<sub>2</sub>O 1.2 mM, NaHCO<sub>3</sub> 25 mM, KH<sub>2</sub>PO<sub>4</sub> 1.2 mM, C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> 11 mM), gassed with 95% O<sub>2</sub>–5% CO<sub>2</sub>, pH 7.4, maintained at 37°C. For the measurement of cardiac functions, a latex balloon filled with double-distilled water was inserted through the mitral valve into the left ventricle (LV) and left ventricular end diastolic pressure (LVEDP), left ventricular developed pressure (LVDP), rate of left ventricular pressure development (d<italic>p</italic>/d<italic>t</italic><sub>max</sub>) and rate of left ventricular pressure decay (d<italic>p</italic>/d<italic>t</italic><sub>min</sub>) were measured using a pressure transducer (Biopac-MP100 system).<sup><xref ref-type="bibr" rid="bibr14-1470320311435534">14</xref></sup></p>
</sec>
<sec id="section13-1470320311435534">
<title>Statistical analysis</title>
<p>All values were expressed as mean ± SD. The data obtained from various groups was statistically analysed using one-way ANOVA followed by Tukey’s multiple range test. A <italic>p</italic> value &lt; 0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec id="section14-1470320311435534" sec-type="results">
<title>Results</title>
<p>The administration of AVE-0991 <italic>per se</italic>, to normal rats produced a decrease in MABP. Further, administration of A-779 to normal rats significantly increased MABP, LVEDP, total LV triglycerides, total urinary proteins, creatinine clearance and significantly reduced LVDP, d<italic>p</italic>/d<italic>t</italic><sub>max</sub>, d<italic>p</italic>/d<italic>t</italic><sub>min</sub> (<xref ref-type="table" rid="table1-1470320311435534">Tables 1</xref> and <xref ref-type="table" rid="table2-1470320311435534">2</xref> and <xref ref-type="fig" rid="fig1-1470320311435534">Figures 1</xref><xref ref-type="fig" rid="fig2-1470320311435534"/><xref ref-type="fig" rid="fig3-1470320311435534"/><xref ref-type="fig" rid="fig4-1470320311435534"/> to <xref ref-type="fig" rid="fig5-1470320311435534">5</xref>),</p>
<table-wrap id="table1-1470320311435534" position="float">
<label>Table 1.</label>
<caption><p>Effect of various pharmacological interventions on total urinary proteins, BUN, creatinine clearance and serum glucose level</p></caption>
<graphic alternate-form-of="table1-1470320311435534" xlink:href="10.1177_1470320311435534-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Group</th>
<th align="left">Total urinary proteins (mg/24 h)</th>
<th align="left">BUN (mg/dl)</th>
<th align="left">Creatinine clearance</th>
<th align="left">Serum glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control (<italic>n</italic> = 9)</td>
<td>6 ± 3.1</td>
<td>20.21 ± 6.4</td>
<td>0.29 ± 0.05</td>
<td>108 ± 11.1</td>
</tr>
<tr>
<td>AVE0991 in normal rats (<italic>n</italic> = 5)</td>
<td>4.5 ± 2.3</td>
<td>22 ± 7.8</td>
<td>0.40 ± 0.14</td>
<td>110.16 ± 4.7</td>
</tr>
<tr>
<td>A-779 in normal rats (<italic>n</italic> = 5)</td>
<td>30 ± 5.2<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref></sup></td>
<td>14 ± 3.3</td>
<td>0.34 ± 0.75</td>
<td>96.5 ± 10</td>
</tr>
<tr>
<td>Diabetic control (<italic>n</italic> = 6)</td>
<td>105 ± 13<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref></sup></td>
<td>93 ± 21.3<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref></sup></td>
<td>0.10 ± 0.03<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref></sup></td>
<td>462 ± 90.2<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref></sup></td>
</tr>
<tr>
<td>AVE0991 in diabetic rats (<italic>n</italic> = 7)</td>
<td>8.3 ± 1.8<sup><xref ref-type="table-fn" rid="table-fn3-1470320311435534">b</xref></sup></td>
<td>39.26 ± 10<sup><xref ref-type="table-fn" rid="table-fn3-1470320311435534">b</xref></sup></td>
<td>0.11 ± 0.06</td>
<td>228.14 ± 21<sup><xref ref-type="table-fn" rid="table-fn3-1470320311435534">b</xref></sup></td>
</tr>
<tr>
<td>A-779 in diabetic rats (<italic>n</italic> = 5)</td>
<td>111 ± 25.2</td>
<td>112 ± 26</td>
<td>0.31 ± 0.11<sup><xref ref-type="table-fn" rid="table-fn3-1470320311435534">b</xref></sup></td>
<td>489 ± 46</td>
</tr>
<tr>
<td>A-779 + AVE0991 in diabetic rats (<italic>n</italic> = 6)</td>
<td>48 ± 11<sup><xref ref-type="table-fn" rid="table-fn4-1470320311435534">c</xref></sup></td>
<td>79 ± 11<sup><xref ref-type="table-fn" rid="table-fn4-1470320311435534">c</xref></sup></td>
<td>0.48 ± 0.08<sup><xref ref-type="table-fn" rid="table-fn2-1470320311435534">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320311435534">b</xref></sup></td>
<td>392 ± 112<sup><xref ref-type="table-fn" rid="table-fn4-1470320311435534">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311435534">
<p>All values are expressed as mean ± SD.</p>
</fn>
<fn id="table-fn2-1470320311435534">
<label>a</label>
<p><italic>p</italic> &lt; 0.05 vs. normal control;</p>
</fn>
<fn id="table-fn3-1470320311435534">
<label>b</label>
<p><italic>p</italic> &lt; 0.05 vs. diabetic control;</p>
</fn>
<fn id="table-fn4-1470320311435534">
<label>c</label>
<p><italic>p</italic> &lt; 0.05 vs. AVE-0991 treated diabetic rats.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1470320311435534" position="float">
<label>Table 2.</label>
<caption><p>Effect of various pharmacological interventions on serum and tissue lipid profile</p></caption>
<graphic alternate-form-of="table2-1470320311435534" xlink:href="10.1177_1470320311435534-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Group</th>
<th align="left">Serum cholesterol (mg/dl)</th>
<th align="left">Serum triglycerides (mg/dl)</th>
<th align="left">Serum HDL (mg/dl)</th>
<th align="left">Total LV cholesterol (μg/mg protein of LV)</th>
<th align="left">Total LV triglyceride (μg/mg protein of LV)</th>
<th align="left">Total renal cholesterol (μg/mg)</th>
<th align="left">Total renal triglyceride (μg/mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control (<italic>n</italic> = 9)</td>
<td>49 ± 7.7</td>
<td>77.6 ± 16.0</td>
<td>36 ± 6.5</td>
<td>50.32 ± 8.0</td>
<td>41.11 ± 6.0</td>
<td>31.00 ± 17.63</td>
<td>27.66 ± 7.00</td>
</tr>
<tr>
<td>AVE-0991 in normal rats (<italic>n</italic> = 5)</td>
<td>49.1 ± 8.4</td>
<td>89 ± 14.8</td>
<td>46 ± 8.0</td>
<td>49 ± 9.0</td>
<td>53 ± 8.3</td>
<td>35.16 ± 9.19</td>
<td>20.35 ± 4.22</td>
</tr>
<tr>
<td>A-779 in normal rats (<italic>n</italic> = 5)</td>
<td>42.3 ± 4.7</td>
<td>93.6 ± 39.8</td>
<td>38.6 ± 4.4</td>
<td>63.3 ± 7.7</td>
<td>70.31 ± 13.0<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
<td>50 ± 3.78</td>
<td>38.12 ± 3.21</td>
</tr>
<tr>
<td>Diabetic control (<italic>n</italic> = 6)</td>
<td>54 ± 7.0</td>
<td>221 ± 52.7<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
<td>38 ± 9.13</td>
<td>80.50 ± 7.3<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
<td>138.25 ± 12.3<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
<td>131.80 ± 20.65<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
<td>124.67 ± 14.69<sup><xref ref-type="table-fn" rid="table-fn6-1470320311435534">a</xref></sup></td>
</tr>
<tr>
<td>AVE-0991 treated diabetic rats (<italic>n</italic> = 7)</td>
<td>57.4 ± 8.6</td>
<td>149.9 ± 10.1<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
<td>68.1 ± 7.7<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
<td>59.41 ± 4.3<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
<td>58.6 ± 10.8<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
<td>77.50 ± 13.65<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
<td>86.93 ± 9.59<sup><xref ref-type="table-fn" rid="table-fn7-1470320311435534">b</xref></sup></td>
</tr>
<tr>
<td>A-779 treated diabetic rats (<italic>n</italic> = 5)</td>
<td>51 ± 7.3</td>
<td>294 ± 26</td>
<td>39.8 ± 5.4</td>
<td>86.10 ± 12.4</td>
<td>145.11 ± 15.0</td>
<td>126.5 ± 42.75</td>
<td>137.4 ± 45.24</td>
</tr>
<tr>
<td>A-779 + AVE-0991 treated diabetic rats (<italic>n</italic> = 6)</td>
<td>62 ± 11.3</td>
<td>288 ± 43.8<sup><xref ref-type="table-fn" rid="table-fn8-1470320311435534">c</xref></sup></td>
<td>37 ± 7.0<sup><xref ref-type="table-fn" rid="table-fn8-1470320311435534">c</xref></sup></td>
<td>90 ± 13.0<sup><xref ref-type="table-fn" rid="table-fn8-1470320311435534">c</xref></sup></td>
<td>112 ± 9.8<sup><xref ref-type="table-fn" rid="table-fn8-1470320311435534">c</xref></sup></td>
<td>110.71 ± 18.38</td>
<td>130.74 ± 16.69<sup><xref ref-type="table-fn" rid="table-fn8-1470320311435534">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1470320311435534">
<p>All values are expressed as mean ± SD.</p>
</fn>
<fn id="table-fn6-1470320311435534">
<label>a</label>
<p><italic>p</italic> &lt; 0.05 vs. normal control;</p>
</fn>
<fn id="table-fn7-1470320311435534">
<label>b</label>
<p><italic>p</italic> &lt; 0.05 vs. diabetic control;</p>
</fn>
<fn id="table-fn8-1470320311435534">
<label>c</label>
<p><italic>p</italic> &lt; 0.05 vs. AVE-0991 treated diabetic rats.</p>
</fn>
<fn id="table-fn9-1470320311435534">
<p>LV: left ventricle.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1470320311435534" position="float">
<label>Figure 1.</label>
<caption><p>Effect of various pharmacological interventions on LVDP. All values are expressed as mean ± SD. <sup>a</sup><italic>p</italic> &lt; 0.05 vs. normal control; <sup>b</sup><italic>p</italic> &lt; 0.05 vs. diabetic control; <sup>c</sup><italic>p</italic> &lt; 0.05 vs. AVE-0991 in DR. DR: diabetic rats, NR: normal rats, LVDP: left ventricular developed pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311435534-fig1.tif"/>
</fig>
<fig id="fig2-1470320311435534" position="float">
<label>Figure 2.</label>
<caption><p>Effect of various pharmacological interventions on <italic>dp/dt</italic><sub>max</sub>. All values are expressed as mean ± SD. <sup>a</sup><italic>p</italic> &lt; 0.05 vs. normal control; <sup>b</sup><italic>p</italic> &lt; 0.05 vs. diabetic control; <sup>c</sup><italic>p</italic> &lt; 0.05 vs. AVE-0991 in DR. DR: diabetic rats, NR: normal rats, <italic>dp/dt</italic><sub>max</sub>: rate of development of left ventricular pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311435534-fig2.tif"/>
</fig>
<fig id="fig3-1470320311435534" position="float">
<label>Figure 3.</label>
<caption><p>Effect of various pharmacological interventions on dp/dtmin. All values are expressed as mean ± SD. <sup>a</sup><italic>p</italic> &lt; 0.05 vs. normal control; <sup>b</sup><italic>p</italic> &lt; 0.05 vs. diabetic control; <sup>c</sup><italic>p</italic> &lt; 0.05 vs. AVE-0991 in DR. DR: diabetic rats, NR: normal rats, <italic>dp/dt</italic><sub>min</sub>: rate of decay of left ventricular pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311435534-fig3.tif"/>
</fig>
<fig id="fig4-1470320311435534" position="float">
<label>Figure 4.</label>
<caption><p>Effect of various pharmacological interventions on LVEDP. All values are expressed as mean ± SD. <sup>a</sup><italic>p</italic> &lt; 0.05 vs. normal control; <sup>b</sup><italic>p</italic> &lt; 0.05 vs. diabetic control; <sup>c</sup><italic>p</italic> &lt; 0.05 vs. AVE-0991 in DR. DR: diabetic rats, NR: normal rats, LVEDP: left ventricular end diastolic pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311435534-fig4.tif"/>
</fig>
<fig id="fig5-1470320311435534" position="float">
<label>Figure 5.</label>
<caption><p>Effect of various pharmacological interventions on MABP. All values are expressed as mean ± SD. <sup>a</sup><italic>p</italic> &lt; 0.05 vs. basal value. DR: diabetic rats, NR: normal rats, MABP: mean arterial blood pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311435534-fig5.tif"/>
</fig>
<sec id="section15-1470320311435534">
<title>Effect of various pharmacological interventions on serum glucose, BUN, proteinuria and serum creatinine in diabetic rats</title>
<p>A significant increase in serum concentration of glucose was noted in diabetic rats. Treatment with AVE-0991 significantly attenuated the increase in serum glucose level in diabetic rats. However, concurrent administration of A-779 significantly blocked the antihyperglycaemic effect AVE-0991 in STZ-treated rats (<xref ref-type="table" rid="table1-1470320311435534">Table 1</xref>).</p>
<p>The concentration of BUN and proteinuria was significantly increased and creatinine clearance was significantly decreased in diabetic rats. Treatment with AVE-0991 significantly decreased BUN and proteinuria in STZ-treated rats. Further, prior treatment with A-779 in the presence of AVE-0991 significantly increased BUN and proteinuria, and produced a significant increase in creatinine clearance compared with the effect in diabetic rats treated with AVE-0991 alone (<xref ref-type="table" rid="table1-1470320311435534">Table 1</xref>).</p>
</sec>
<sec id="section16-1470320311435534">
<title>Effect of various pharmacological interventions on the lipid profile in diabetic rats</title>
<p>A significant increase in serum triglycerides, total LV cholesterol, total LV triglycerides, renal cholesterol and renal triglycerides was noted in diabetic control rats. No significant change in serum cholesterol and serum HDL level was observed. Treatment with AVE-0991 significantly reduced serum triglycerides, total LV cholesterol, total LV triglycerides, renal cholesterol, renal triglycerides and significantly increased serum HDL levels. Pre-treatment with A-779 significantly attenuated the AVE-0991-induced changes in lipid profile in diabetic rats (<xref ref-type="table" rid="table2-1470320311435534">Table 2</xref>).</p>
</sec>
<sec id="section17-1470320311435534">
<title>Effect of various pharmacological interventions on haemodynamic parameters in diabetic rats</title>
<p>A significant decrease in LVDP, d<italic>p</italic>/d<italic>t</italic><sub>max</sub> and d<italic>p</italic>/d<italic>t</italic><sub>min</sub> and a significant increase in LVEDP was noted in diabetic control rats. Treatment with AVE-0991 significantly increased LVDP and d<italic>p</italic>/d<italic>t</italic><sub>max</sub> and significantly decreased LVEDP in STZ-treated rats. Further, pre-treatment with A-779 plus AVE-0991 in diabetic rats significantly decreased LVDP, d<italic>p</italic>/d<italic>t</italic><sub>max</sub> and d<italic>p</italic>/d<italic>t</italic><sub>min</sub> and significantly increased LVEDP when compared with diabetic rats treated with AVE-0991 alone (<xref ref-type="fig" rid="fig1-1470320311435534">Figures 1</xref><xref ref-type="fig" rid="fig2-1470320311435534"/><xref ref-type="fig" rid="fig3-1470320311435534"/>–<xref ref-type="fig" rid="fig4-1470320311435534">4</xref>).</p>
<p>A significant increase in MABP was noted in diabetic control rats as compared with their baseline. Treatment with both AVE-0991 alone and in combination with A-779 did not produce any significant change in MABP in diabetic rats (<xref ref-type="fig" rid="fig5-1470320311435534">Figure 5</xref>).</p>
</sec>
</sec>
<sec id="section18-1470320311435534" sec-type="discussion">
<title>Discussion</title>
<p>The new findings of this study are that treatment with AVE-0991 significantly attenuates STZ-induced cardio-renal dysfunction in Wister rats. Further, AVE-0991 treatment, for the first time, has been shown to reduce dyslipidaemia and produce significant antihyperglycaemic activity in STZ-treated rats. Prior administration of A-779 significantly antagonised the effects of exogenously administrated AVE-0991 in diabetic rats, indicating that these effects are mediated through the Mas receptor.</p>
<p>Lipid metabolism plays an important role in the development and progression of cardiac and renal dysfunction in diabetes.<sup><xref ref-type="bibr" rid="bibr26-1470320311435534">26</xref>,<xref ref-type="bibr" rid="bibr27-1470320311435534">27</xref></sup> In our study too, the increase in serum and tissue lipid levels was associated with significant change in cardiac and renal function, e.g. an increase in LVEDP, BUN, protein urea and decrease in LVDP, d<italic>p</italic>/d<italic>t</italic><sub>max</sub>, and d<italic>p</italic>/d<italic>t</italic><sub>min</sub> in diabetic rats.</p>
<p>It has been reported that RAAS play an important role in lipid metabolism.<sup><xref ref-type="bibr" rid="bibr28-1470320311435534">28</xref></sup> Mas-deficient mice exhibited a significant increase in angiotensinogen expression in adipose tissue, suggesting that the ang-(1–7)/Mas axis regulates angiotensinogen expression in fat tissue,<sup><xref ref-type="bibr" rid="bibr12-1470320311435534">12</xref></sup> while transgenic rats with increased levels of angiotensin (1–7) show improved lipid metabolism.<sup><xref ref-type="bibr" rid="bibr29-1470320311435534">29</xref></sup> Also, we have recently reported that chronic treatment with angiotensin (1–7) attenuated dyslipidaemia in diabetic rats.<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref>,<xref ref-type="bibr" rid="bibr14-1470320311435534">14</xref></sup> The results obtained in the present study have demonstrated, for the first time, that exogenous administration of AVE-0991 decreases serum triglycerides, LV triglycerides, LV cholesterol, renal triglycerides and renal cholesterol levels, increases serum HDL levels, and mimics the action of angiotensin (1–7) in diabetic rats.</p>
<p>The possible molecular mechanism of attenuation of dyslipidaemia by activation of the ACE-2/Ang (1–7)/Mas-receptor axis in diabetic rats is not fully understood. It may be due to decreased levels of leptin, increased production of adiponectin in the adipose tissue<sup><xref ref-type="bibr" rid="bibr29-1470320311435534">29</xref></sup> and increased renal expression of PPAR-γ mRNA in rats.<sup><xref ref-type="bibr" rid="bibr30-1470320311435534">30</xref></sup> AVE-0991-induced improvements in the lipid profile in our study can be explained on this basis.</p>
<p>It has been reported that activation of the Mas receptor played a beneficial role in glucose metabolism.<sup><xref ref-type="bibr" rid="bibr31-1470320311435534">31</xref></sup> Transgenic rats over-expressing angiotensin (1–7) show increased glucose tolerance and insulin sensitivity, possibly by inhibition of insulin receptor/IRS-1/PI3K/Akt signalling, and through decreased phosphorylation of the inhibitory site IRS-1/Ser307 in adipose tissue.<sup><xref ref-type="bibr" rid="bibr29-1470320311435534">29</xref></sup> In this study, for the first time, AVE-0991 showed antihyperglycaemic activity in STZ-treated rats. However, in our earlier studies, the administration of angiotensin (1–7) to diabetic rats had no significant effect on serum glucose level.<sup><xref ref-type="bibr" rid="bibr13-1470320311435534">13</xref>,<xref ref-type="bibr" rid="bibr16-1470320311435534">16</xref></sup> The mechanism of differential effect of the two Mas-receptor agonists, needs to be investigated further.</p>
<p>Angiotensin (1–7) Mas-receptor axis activation produces vasodilation in various experimental models through activation of the PI3K/Akt pathway.<sup><xref ref-type="bibr" rid="bibr32-1470320311435534">32</xref></sup> Both AVE-0991 and angiotensin (1–7) were equipotent in inducing concentration-dependent vasodilator effects in isolated murine aortic rings.<sup><xref ref-type="bibr" rid="bibr6-1470320311435534">6</xref>,<xref ref-type="bibr" rid="bibr12-1470320311435534">12</xref>,<xref ref-type="bibr" rid="bibr33-1470320311435534">33</xref></sup> However, this effect was dependent on the presence of intact endothelium. Further, vascular endothelial dysfunction is reported to be a major contributor for the development and progression of secondary complications of diabetes.<sup><xref ref-type="bibr" rid="bibr34-1470320311435534">34</xref></sup> Therefore, the lack of an antihypertensive effect of AVE-0991 may be due to damaged endothelium in diabetic rats, as both AVE-0991 and A-779, <italic>per se</italic>, produced changes in blood pressure in normal rats with intact endothelium.</p>
<p>Accumulating evidence indicates that diabetic nephropathy (DN) is a major risk factor for cardiovascular disorders.<sup><xref ref-type="bibr" rid="bibr35-1470320311435534">35</xref><xref ref-type="bibr" rid="bibr36-1470320311435534"/>-<xref ref-type="bibr" rid="bibr37-1470320311435534">37</xref></sup> In the present study too, BUN and proteinuria were noted to be increased and creatinine clearance was significantly decreased in diabetic rats with cardiomyopathy. AVE-0991 administration had no significant effect on markers of DN, while A-779, a specific antagonist of the Mas receptor, significantly increased total urinary proteins in the normal rats. Treatment with AVE-0991, for the first time, has been shown to significantly attenuate the diabetes-induced increase in protein urea and BUN, but did not improve creatinine clearance in diabetic rats. Thus, AVE-0991 mimics the renal-protective effects of angiotensin (1–7) in this regard.<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref></sup> Prior administration of A-779 significantly antagonised the effects of exogenously administrated AVE-0991 in the diabetic rats, and produced an unexpected significant increase in creatinine clearance. The exact mechanism of this unexpected action of A-779 is not known. Therefore, activation of the Mas receptor by its specific agonists may produce cardio-protective effects by improving renal function, in diabetic rats.</p>
<p>Endogenous activation of the Mas receptor plays a physiological role in the body, as administration of both AVE-0991 and A-779 produced effects in normal rats as reported previously by our group.<sup><xref ref-type="bibr" rid="bibr8-1470320311435534">8</xref>,<xref ref-type="bibr" rid="bibr14-1470320311435534">14</xref></sup></p>
<p>It may be concluded that STZ administration produced persistent hyperglycaemia, dyslipidaemia and hypertension in Wister rats, which consequently produced myocardial and renal dysfunction. For the first time, AVE-0991 treatment has been shown to produce cardio-renal protective effects, possibly due to improvement in glucose and lipid metabolism, as no significant changes were observed in blood pressure in diabetic rats.</p>
<sec id="section19-1470320311435534">
<title>Clinical implication of this study</title>
<p>Cardio-renal damage is a long-term complication in diabetic patients. The cardio-renal protective effect of Mas-receptor agonists in diabetic rats provides a potential, new therapeutic approach to minimise this risk.</p>
</sec>
</sec>
</body>
<back>
<ack><p>We are grateful to sanofi–aventis, Germany, for the <italic>ex gratia</italic> supply of AVE-0991. We wish to express our gratitude to Mr Parveen Garg, Chairman, ISF College of Pharmacy, Moga, Punjab, India, for his inspiration and constant support.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by a research grant from the All India Council for Technical Education, New Delhi (File no. 8023/BOR/RID/RPS-167/2007-08).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311435534">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kannel</surname><given-names>WB</given-names></name>
<name><surname>Hjortland</surname><given-names>M</given-names></name>
<name><surname>Castellim</surname><given-names>WP.</given-names></name>
</person-group> <article-title>Role of diabetes in congestive heart failure: the Framingham study</article-title>. <source>Am J Cardiol</source> <year>1974</year>; <volume>34</volume>: <fpage>29</fpage>–<lpage>34</lpage></citation>
</ref>
<ref id="bibr2-1470320311435534">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhalla</surname><given-names>NS</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Panagia</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Subcellular remodelling and heart dysfunction in chronic diabetes</article-title>. <source>Cardiovasc Res</source> <year>1998</year>; <volume>40</volume>: <fpage>239</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311435534">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dronavalli</surname><given-names>S</given-names></name>
<name><surname>Duka</surname><given-names>I</given-names></name>
<name><surname>Babris</surname><given-names>GL.</given-names></name>
</person-group> <article-title>The pathogenesis of diabetic nephropathy</article-title>. <source>Nat Clin Prac Endocrinol Metab</source> <year>2008</year>; <volume>4</volume>: <fpage>444</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311435534">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donoghue</surname><given-names>M</given-names></name>
<name><surname>Hsieh</surname><given-names>F</given-names></name>
<name><surname>Baronas</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9</article-title>. <source>Circ Res</source> <year>2000</year>; <volume>87</volume>: <fpage>E1</fpage>–<lpage>E9</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311435534">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santos</surname><given-names>RA</given-names></name>
<name><surname>Campagnole-Santos</surname><given-names>MJ</given-names></name>
<name><surname>Andrade</surname><given-names>SP.</given-names></name>
</person-group> <article-title>Angiotensin-(1–7): an update</article-title>. <source>Regul Pept</source> <year>2000</year>; <volume>91</volume>: <fpage>45</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311435534">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinheiro</surname><given-names>SV</given-names></name>
<name><surname>Simoes</surname><given-names>e</given-names></name>
<name><surname>Silva</surname><given-names>AC</given-names></name>
<name><surname>Sampaio</surname><given-names>WO</given-names></name><etal/>
</person-group>. <article-title>Nonpeptide AVE-0991 is an angiotensin-(1–7) receptor Mas agonist in the mouse kidney</article-title>. <source>Hypertension</source> <year>2004</year>; <volume>44</volume>: <fpage>490</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311435534">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>AJ</given-names></name>
<name><surname>Santos</surname><given-names>RAS</given-names></name>
</person-group>. <article-title>Cardiovascular actions of angiotensin-(1–7)</article-title>. <source>Braz J Med Biol Res</source> <year>2005</year>; <volume>38</volume>: <fpage>499</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311435534">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>T</given-names></name>
<name><surname>Singh</surname><given-names>K</given-names></name>
<name><surname>Sharma</surname><given-names>PL.</given-names></name>
</person-group> <article-title>Ameliorative potential of angiotensin1–7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats</article-title>. <source>Meth Find Exp Clin Pharmacol</source> <year>2010</year>; <volume>32</volume>: <fpage>19</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311435534">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grobe</surname><given-names>JL</given-names></name>
<name><surname>Der</surname><given-names>Â</given-names></name>
<name><surname>Sarkissian</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts</article-title>. <source>Clin Sci (Lond)</source> <year>2007</year>; <volume>113</volume>: <fpage>357</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311435534">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santos</surname><given-names>RAS</given-names></name>
<name><surname>Castro</surname><given-names>CH</given-names></name>
<name><surname>Gava</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor Mas knockout mice</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>47</volume>: <fpage>996</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311435534">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>K</given-names></name>
<name><surname>Iyer</surname><given-names>SN</given-names></name>
<name><surname>Chappell</surname><given-names>MC</given-names></name>
<etal/>
</person-group>. <article-title>Converting enzyme determines plasma clearance of angiotensin (1–7)</article-title>. <source>Hypertension</source> <year>1998</year>; <volume>32</volume>: <fpage>496</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311435534">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiemer</surname><given-names>G</given-names></name>
<name><surname>Dobrucki</surname><given-names>LW</given-names></name>
<name><surname>Louka</surname><given-names>FR</given-names></name>
<etal/>
</person-group>. <article-title>AVE-0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium</article-title>. <source>Hypertension</source> <year>2002</year>; <volume>40</volume>: <fpage>847</fpage>–<lpage>852</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311435534">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benter</surname><given-names>IF</given-names></name>
<name><surname>Yousif</surname><given-names>MHM</given-names></name>
<name><surname>Anim</surname><given-names>JT</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2007</year>; <volume>292</volume>: <fpage>H666</fpage>–<lpage>H672</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311435534">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>K</given-names></name>
<name><surname>Singh</surname><given-names>T</given-names></name>
<name><surname>Sharma</surname><given-names>PL.</given-names></name>
</person-group> <article-title>Beneficial effects of angiotensin (1–7) in diabetic rats with cardiomyopathy</article-title>. <source>Ther Adv Cardiovas Dis</source> <year>2011</year>; <volume>5</volume>; <fpage>159</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311435534">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Maghrebi</surname><given-names>M</given-names></name>
<name><surname>Benter</surname><given-names>IF</given-names></name>
<name><surname>Diz</surname><given-names>DI.</given-names></name>
</person-group> <article-title>Endogenous angiotensin-(1–7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats</article-title>. <source>Pharmacol Res</source> <year>2009</year>; <volume>59</volume>: <fpage>263</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311435534">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trinder</surname><given-names>P.</given-names></name>
</person-group> <article-title>Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor</article-title>. <source>Ann Clin Biochem</source> <year>1969</year>; <volume>6</volume>: <fpage>24</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311435534">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allain</surname><given-names>CC</given-names></name>
<name><surname>Poon</surname><given-names>LS</given-names></name>
<name><surname>Chan</surname><given-names>CSG</given-names></name>
<etal/>
</person-group>. <article-title>Enzymatic determination of total serum cholesterol</article-title>. <source>Clin Chem</source> <year>1974</year>; <volume>20</volume>: <fpage>470</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311435534">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folch</surname><given-names>J</given-names></name>
<name><surname>Lees</surname><given-names>M</given-names></name>
<name><surname>Sloane-Stanley</surname><given-names>GH.</given-names></name>
</person-group> <article-title>A simple method for isolation and purification of total lipids from animal tissue</article-title>. <source>J Biol Chem</source> <year>1956</year>; <volume>226</volume>: <fpage>497</fpage>–<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311435534">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deepa</surname><given-names>PR</given-names></name>
<name><surname>Varalakshmi</surname><given-names>P.</given-names></name>
</person-group> <article-title>Beneficial cardio-renovascular effects of low-molecular-weight heparin-derivative on adriamycin-induced glycosaminoglycanuria and tissue lipid abnormalities</article-title>. <source>Toxicology</source> <year>2005</year>; <volume>211</volume>: <fpage>77</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311435534">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cho</surname><given-names>BHS</given-names></name>
</person-group>. <article-title>Improved enzymatic determination of total cholesterol in tissues</article-title>. <source>Clin Chem</source> <year>1983</year>; <volume>29</volume>: <fpage>166</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311435534">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonsnes</surname><given-names>RW</given-names></name>
<name><surname>Taussky</surname><given-names>HH.</given-names></name>
</person-group> <article-title>On the colorimetric determination of creatinine by the Jaffe reaction</article-title>. <source>J Biol Chem</source> <year>1945</year>; <volume>158</volume>: <fpage>581</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr22-1470320311435534">
<label>22.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Shargel</surname><given-names>L</given-names></name>
<name><surname>Wu-Pong</surname><given-names>S</given-names></name>
<name><surname>Yu</surname><given-names>ABC</given-names></name>
</person-group>. <article-title>Serum creatinine and creatinine clearance</article-title>. <source>Applied biopharmaceutics and pharmacokinetics</source>, <volume>vol. 1</volume>. <publisher-loc>New Delhi</publisher-loc>: <publisher-name>McGraw Hill</publisher-name>, <year>2005</year>, pp. <fpage>678</fpage>–<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr23-1470320311435534">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fawcett</surname><given-names>JK</given-names></name>
<name><surname>Scott</surname><given-names>JE.</given-names></name>
</person-group> <article-title>A rapid and precise method for the determination of urea</article-title>. <source>J Clin Pathol</source> <year>1960</year>; <volume>13</volume>: <fpage>156</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr24-1470320311435534">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Kamei</surname><given-names>S</given-names></name>
<name><surname>Ohkubo</surname><given-names>A</given-names></name>
 <etal/>
</person-group>. <article-title>Urinary protein as measured with a pyrogallol red–molybdate complex, manually and in a Hitachi 726 automated analyzer</article-title>. <source>Clin Chem</source> <year>1986</year>; <volume>32</volume>: <fpage>1551</fpage>–<lpage>1554</lpage>.</citation>
</ref>
<ref id="bibr25-1470320311435534">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>Y</given-names></name>
<name><surname>Lee</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>54</volume>: <fpage>591</fpage>–<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr26-1470320311435534">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keane</surname><given-names>WF.</given-names></name>
</person-group> <article-title>The role of lipids in renal disease: Future challenges</article-title>. <source>Kidney Int</source> <year>2000</year>; <volume>57</volume>: <fpage>S27</fpage>–<lpage>S31</lpage>.</citation>
</ref>
<ref id="bibr27-1470320311435534">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finck</surname><given-names>BN</given-names></name>
<name><surname>Han</surname><given-names>X</given-names></name>
<name><surname>Courtois</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2003</year>; <volume>100</volume>: <fpage>1226</fpage>–<lpage>1231</lpage>.</citation>
</ref>
<ref id="bibr28-1470320311435534">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jayasooria</surname><given-names>AP</given-names></name>
<name><surname>Mathai</surname><given-names>ML</given-names></name>
<name><surname>Walker</surname><given-names>LL</given-names></name><etal/>
</person-group>. <article-title>Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2008</year>; <volume>105</volume>: <fpage>6531</fpage>–<lpage>6536</lpage>.</citation>
</ref>
<ref id="bibr29-1470320311435534">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santos</surname><given-names>SH</given-names></name>
<name><surname>Braga</surname><given-names>JF</given-names></name>
<name><surname>Mario</surname><given-names>EG</given-names></name>
<etal/>
</person-group>. <article-title>Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1–7)</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2010</year>; <volume>30</volume>: <fpage>953</fpage>–<lpage>961</lpage>.</citation>
</ref>
<ref id="bibr30-1470320311435534">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhaunsi</surname><given-names>GS</given-names></name>
<name><surname>Yousif</surname><given-names>MHM</given-names></name>
<name><surname>Akhtar</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Angiotensin (1–7) prevents diabetes-induced attenuation in PPAR-γ and catalase activities</article-title>. <source>Eur J Pharmacol</source> <year>2010</year>; <volume>638</volume>: <fpage>108</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr31-1470320311435534">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walter</surname><given-names>T</given-names></name>
<name><surname>Balschum</surname><given-names>D</given-names></name>
<name><surname>Voigit</surname><given-names>JP</given-names></name>
<etal/>
</person-group>. <article-title>Sustined long-term potentiation and anxiety in mice lacking the Mas protoncogene</article-title>. <source>J Biol Chem</source> <year>1998</year>; <volume>273</volume>: <fpage>11867</fpage>–<lpage>11873</lpage>.</citation>
</ref>
<ref id="bibr32-1470320311435534">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sampaio</surname><given-names>WO</given-names></name>
<name><surname>Santos</surname><given-names>RAS</given-names></name>
<name><surname>Faria-Silva</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways</article-title>. <source>Hypertension</source> <year>2007</year>; <volume>49</volume>: <fpage>185</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr33-1470320311435534">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemos</surname><given-names>VS</given-names></name>
<name><surname>Silva</surname><given-names>DM</given-names></name>
<name><surname>Walther</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>The endothelium-dependent vasodilator effect of the nonpeptide Ang-(1–7) mimic AVE-0991 is abolished in the aorta of Mas-knockout mice</article-title>. <source>J Cardiovasc Pharmacol</source> <year>2005</year>; <volume>46</volume>: <fpage>274</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr34-1470320311435534">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Mise</surname><given-names>N</given-names></name>
<name><surname>Pisoni</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies</article-title>. <source>Circulation</source> <year>2003</year>; <volume>107</volume>: <fpage>586</fpage>–<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr35-1470320311435534">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<name><surname>Mann</surname><given-names>JFE</given-names></name>
<name><surname>Yi</surname><given-names>Q</given-names></name>
<etal/>
</person-group>. <article-title>Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals</article-title>. <source>JAMA</source> <year>2001</year>; <volume>286</volume>: <fpage>421</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr36-1470320311435534">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mann</surname><given-names>JF</given-names></name>
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<name><surname>Pogue</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial</article-title>. <source>Ann Intern Med</source> <year>2001</year>; <volume>134</volume>: <fpage>629</fpage>–<lpage>636</lpage>.</citation>
</ref>
<ref id="bibr37-1470320311435534">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adler</surname><given-names>AI</given-names></name>
<name><surname>Stevens</surname><given-names>RJ</given-names></name>
<name><surname>Manley</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)</article-title>. <source>Kidney Int</source> <year>2003</year>; <volume>63</volume>: <fpage>225</fpage>–<lpage>232</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>